


**Product Name** : Umbralisib  
**Cat. No.** : PC-42941  
**CAS No.** : 1532533-67-7  
**Molecular Formula** : C<sub>31</sub>H<sub>24</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>  
**Molecular Weight** : 571.5492  
**Target** : PI3K  
**Solubility** : 10 mM in DMSO



## Biological Activity

Umbralisib (RP5264, TGR1202, TGR-1202) is a potent, selective, orally available **PI3Kδ** inhibitor with IC<sub>50</sub> of 22 nM, 50-fold selectivity over PI3Kα/β and >10,000 fold over PI3Kγ.

TGR1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest, demonstrates highly synergistic effect with the proteasome inhibitor carfilzomib in lymphoma, leukemia, and myeloma cell lines and primary lymphoma and leukemia cells

TGR1202 synergistically disrupts the 4E-BP1-eIF4F-c-Myc axis with carfilzomib, also potently inhibits 60% of the activity of **CK1ε** at 1 uM.

## References

Locatelli SL, et al. **Leukemia**. 2016 Dec;30(12):2402-2405.

Deng C, et al. **Blood**. 2017 Jan 5;129(1):88-99.

Burris HA 3rd, et al. **Lancet Oncol**. 2018 Feb 20. pii: S1470-2045(18)30082-2.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com